Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
-
- If successful, paltusotine would offer acromegaly patients a once-daily oral treatment option - SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a...
-
SAN DIEGO, June 16, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
-
Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021 Phase 1 data for CRN04894 and CRN04777 expected in mid-2021 SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Crinetics...
-
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
-
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
-
Advancing paltusotine into a Phase 3 program for acromegaly following an FDA meeting Phase 1 clinical proof-of-concept data for CRN04894 and CRN04777 expected in 1H 2021 and mid-2021, respectively ...
-
SAN DIEGO, March 24, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
-
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
-
- Details of New Paltusotine Tablet Formulation to be Unveiled - - Preclinical Evidence Supporting Programs in Congenital Hyperinsulinism and Congenital Adrenal Hyperplasia and Cushing’s Disease...